insulin degludec (Tresiba)

From Aaushi
Jump to navigation Jump to search

Introduction

FDA approves Sept 2015.

Indications

Dosage

  • start 10 units SQ QD or 20 units SQ three times a week

Pharmacokinetics

  • 1/2 life > 25 hours
  • duration of action (>40 hours)*

* roughly twice that of insulin glargine (Lantus)

Adverse effects

Notes

  • too expensive[5]

More general terms

Component of

References

  1. 1.0 1.1 Heller S et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 Apr 21; 379:1489 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22521071
  2. 2.0 2.1 Garber AJ et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 Apr 21; 379:1498 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22521072
  3. Zinman B et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012 Dec; 35:2464 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23043166
  4. FDA News Release. September 25, 2015 FDA approves two new drug treatments for diabetes mellitus http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm464321.htm
  5. 5.0 5.1 California Institute for Clinical and Economic Review, 2015 Insulin Degludec (Tresiba<TM>, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks. http://ctaf.org/sites/default/files/u148/Diabetes_Draft_Report_122115.pdf
  6. 6.0 6.1 Lane W, Bailey TS, Gerety G et al Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes. The SWITCH 1 Randomized Clinical Trial. JAMA. 2017;318(1):33-44 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28672316 <Internet> http://jamanetwork.com/journals/jama/article-abstract/2635629
    Wysham C, Bhargava A, Chaykin L et al Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. The SWITCH 2 Randomized Clinical Trial. JAMA. 2017;318(1):45-56. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28672317 <Internet> http://jamanetwork.com/journals/jama/article-abstract/2635630
    Seaquist ER, Chow LS Hypoglycemia in Diabetes. Does Insulin Type Matter? JAMA. 2017;318(1):31-32 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28672298 <Internet> http://jamanetwork.com/journals/jama/article-abstract/2635610